What AqueaTether Therapeutics does

AqueaTether Therapeutics is a privately held biotechnology company operating as a dedicated division of CellMosaic, headquartered in Woburn, Massachusetts. Founded in 2008, the company has developed the proprietary AqueaTether (AqT) drug delivery platform, which uses super-hydrophilic, highly water-soluble linkers derived from edible sugar alcohols (mannitol) to enable efficient loading of hydrophobic drug payloads onto antibodies for antibody-drug conjugate (ADC) development. The platform claims advantages over conventional linkers, including higher drug-to-antibody ratios (up to 8 drugs per antibody), reduced aggregation (under 2% vs. 10-50% for classical linkers), and improved aqueous solubility and stability. AqueaTether offers a portfolio of six pre-developed AqT-Drug conjugate assets (AqT-Calicheamicin, AqT-Exatecan, AqT-MMAE, AqT-MMAF, AqT-SN38, and AqT-UM171) for partner evaluation.

The company's revenue model combines custom bioconjugation services, sale of pre-developed drug assets, technology licensing (including manufacturing transfer), and structured development partnerships (including joint ventures and equity partnerships), supplemented by non-dilutive NIH and Department of Defense grant funding. The go-to-market is direct and B2B: pharmaceutical and biotechnology companies engage via Material Transfer Agreements for no-cost proof-of-concept evaluation, followed by negotiated licensing or partnership agreements for full ADC development. The technology has been validated by the FY14 DoD Breast Cancer Research Program Breakthrough Award, and the platform is protected by issued and allowed patents worldwide on composition matter and conjugation processes.

Name

AqueaTether Therapeutics

Legal name

AqueaTether Therapeutics

Website

https://aqttherapeutics.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

AqueaTether Therapeutics is a privately held biotech division of CellMosaic developing proprietary sugar alcohol-derived (AqT) linkers for next-generation antibody-drug conjugates, serving pharmaceutical and biotechnology partners through licensing, services, and development partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Conjugates

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Antibody-drug conjugates
• Drug conjugation technology
• Bioconjugation services
• Pharmaceutical development
• Targeted cancer therapy

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Bioconjugation Services: Custom bioconjugation services at standard rates for preparing AqT ADCs at CellMosaic facilities. Initial evaluation available under MTA with no accessing or license fee for short timeline and low cost development screening.
2. AqT Drug Assets: Sale of pre-developed AqT-drug conjugate assets for partner evaluation and development including AqT-Calicheamicin, AqT-Exatecan, AqT-MMAE, AqT-MMAF, AqT-SN38, and AqT-UM171.
3. Technology Licensing: Licensing of AqT platform technologies for full ADC development with options for technology transfer to partners for manufacturing scale-up.
4. Development Partnerships: Strategic partnerships including development collaborations, joint ventures, equity partnerships, and grant mechanisms for full ADC discovery, development and manufacturing.
5. NIH and DoD Grant Funding: Non-dilutive funding from NIH and Department of Defense grants including the FY14 DoD Breast Cancer Research Program Breakthrough Award.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

AqueaTether Therapeutics develops and provides the proprietary AqueaTether (AqT) drug delivery platform, which uses sugar alcohol-derived super-hydrophilic linkers (based on mannitol) for antibody-drug conjugate (ADC) development and bioconjugation. The company sells a portfolio of pre-developed AqT-Drug conjugate assets (Calicheamicin, Exatecan, MMAE, MMAF, SN38, and UM171) and offers custom bioconjugation services, technology licensing, and full ADC development partnerships to pharmaceutical and biotech companies for cancer therapeutics.

Product overview

AqueaTether Therapeutics, a division of CellMosaic founded in 2008, offers the AqT® ADC Platform—a proprietary drug conjugation and delivery technology based on super-hydrophilic sugar alcohol-derived linkers. The platform supports a portfolio of AqT®-Drug Assets including Calicheamicin, Exatecan, MMAE, MMAF, SN38, and UM171 conjugates. These technologies enable pharmaceutical and biotech partners to develop next-generation antibody-drug conjugates with improved drug loading capacity (up to 8 drugs per antibody), enhanced aqueous solubility, reduced aggregation, and controlled drug release for safer, more effective cancer therapies.

Differentiator

Problem solved

Functional benefit

Brands

• AqT ADC Platform: Proprietary AqueaTether drug delivery technology platform for drug conjugation and delivery using linkers derived from edible sugar alcohols.
• AqT-Drug Assets

Products and services

• AqT® ADC Platform A proprietary drug conjugation and delivery platform using sugar alcohol-derived super-hydrophilic linkers (AqueaTether®) that enables efficient loading of hydrophobic drug payloads onto antibodies, creating antibody-drug conjugates (ADCs) with improved solubility, stability, and reduced aggregation. Targeted at pharmaceutical and biotech companies developing next-generation cancer therapeutics.
• AqT®-Calicheamicin (CM81307) A next-generation ADC payload using site-specific reduced-thiol labeling with a releasable linker, enabling efficient loading of four to six drug molecules per antibody with minimal aggregation. Available for partner evaluation and licensing.
• AqT®-Exatecan (CM81314) A topoisomerase inhibitor (TopI and TopII) ADC payload using site-specific labeling with a releasable VC-PAB linker, enabling efficient loading of up to eight drug molecules per antibody with minimal aggregation. Available for partner evaluation and licensing.
• AqT®-MMAE (CM81303) A tubulin inhibitor ADC payload using reduced-thiol conjugation chemistry with a releasable VC-PAB linker, enabling efficient loading of up to eight drug molecules per antibody with minimal aggregation and improved stability. Available for partner evaluation and licensing.
• AqT®-MMAF (CM81306) A synthetic antimitotic ADC payload using reduced-thiol chemistry with a releasable VC-PAB linker, enabling efficient loading of up to eight drug molecules per antibody with minimal aggregation and improved stability. Available for partner evaluation and licensing.
• AqT®-SN38 (CM81301) A topoisomerase I inhibitor ADC payload using proprietary super-hydrophilic AqT linker with releasable ester bond chemistry, enabling high loading of 5-7 SN38 molecules per antibody with minimal aggregation and traceless release. Available for partner evaluation and licensing.
• AqT®-UM171 (CM81310) A human hematopoietic stem cell self-renewal agonist ADC payload using super-hydrophilic AqT linker to overcome the high hydrophobicity of UM171, enabling efficient loading of four to six drug molecules per antibody without significant precipitation (compared to 38% aggregation with ethylene linker). Available for partner evaluation and licensing.
• Custom Bioconjugation Services Custom bioconjugation services offered at standard rates for preparing AqT ADCs at CellMosaic facilities. Initial evaluation is available under Material Transfer Agreement (MTA) with no access or license fee for short timeline and low-cost development screening (1-3 mg up to total 30 mg AqT-ADC per drug). Targeted at pharmaceutical and biotech partners seeking rapid conjugate preparation.
• Technology Licensing & Development Partnerships Licensing of the AqT platform technologies for full ADC development with options for technology transfer to partners for manufacturing scale-up. Also includes strategic development partnerships including joint ventures, equity partnerships, and grant mechanisms for full ADC discovery, development, and manufacturing. Targeted at pharmaceutical and biotech companies seeking full-scale ADC program development.

Quantifiable outcome

• Drug loading up to 8 drugs per antibody with minimal aggregation (less than 2% added aggregation vs 10-50% with classical linkers)
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Direct peers

• Heidelberg Pharma: Clinical-stage developer of ADCs using proprietary linker technology (incl. amanitin-based payloads). Direct competitor to AqueaTether in differentiated ADC linker/payload space, also licensing to pharma partners.
• LegoChem Biosciences: Korean biotech developing site-specific ADC conjugation using proprietary linker chemistry and offering licensing deals to pharma. Closely comparable technology platform and business model to AqueaTether.
• Mersana Therapeutics: Clinical-stage ADC company using proprietary Dolaflexin and other platforms to address DAR/aggregation challenges. Competes on linker and payload innovation targeting the same oncology customers.
• Sutro Biopharma: Cell-free protein synthesis platform for site-specific ADCs and bispecifics. Comparable technology-platform-plus-pipeline business model and partnership orientation.
• Concortis Biotherapeutics (Zafgen successor): Preclinical ADC company with proprietary linker/conjugation chemistry; very similar positioning to AqueaTether as a small ADC technology platform seeking pharma partnerships.
• Byondis: Dutch biotech with proprietary linker (HydraSpace) and ADC pipeline; comparable mid-size linker-focused player seeking pharma licensing partnerships.

Broad incumbents

• ImmunoGen (AbbVie): Long-established ADC developer (now AbbVie) with approved products (Kadcyla, Elahere). Sets the competitive standard for ADC linker chemistry and partners/customers any small platform company must court.
• Catalent (Novo Holdings): Largest bioconjugation and ADC contract manufacturer offering similar linker services and bioconjugation capabilities to AqueaTether, but at vastly greater scale and with broader service portfolio.

Emerging players

• Bolt Biotherapeutics: Clinical-stage developer of immune-stimulating ADCs. Comparable as a small platform-plus-pipeline ADC company, though differentiated by its immune-stimulatory mechanism.
• Pyxis Oncology: ADC-focused oncology biotech with proprietary linker technology (through legacy Levena Biopharma assets). Comparable small-cap platform-plus-pipeline ADC business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AqueaTether Therapeutics